Aspira Pathlab & Diagnostics Ltd. engages in the operation of diagnostic centers and laboratories. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-12-05. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The firm carries out pathological investigations in various branches, including biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The firm's tests include COVID-19 tests, health packages and pathology tests. Its COVID-19 tests include Shanti Screening Test, COVID-19 Antibody Test, COVID-19 Surveillance Profile, COVID-19 RT-PCR Test, COVID-19 Detection Profile 1 and COVID-19 Detection Profile 2.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.